Fludarabine Phosphate: Brands, Price & Uses in Bangladesh

Fludarabine Phosphate is a purine analog antineoplastic (chemotherapy) agent used under specialist oncology supervision.

Established / FDA-approved use

• Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during or after treatment with, at least one standard alkylating-agent-containing regimen.

Guideline-supported / adjunct uses (often combination therapy)

• Certain low-grade non-Hodgkin lymphomas, typically used in combination regimens (e.g. with cyclophosphamide and/or rituximab).
• Reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation, as part of a multi-agent conditioning protocol.

Off-label use

• Used off-label in some FLAG/FLAG-IDA type combination regimens for relapsed/refractory acute myeloid leukemia, under specialist protocols only.

Fludarabine Phosphate is a specialist chemotherapy medicine; it must only be prescribed, dispensed, and administered by or under the direct supervision of a qualified oncologist/hematologist experienced in cancer chemotherapy.

Per-indication dosing of Fludarabine Phosphate

Renal impairment

• Creatinine clearance 30-70 mL/min: reduce the dose of Fludarabine Phosphate (commonly by up to 20%) and monitor closely for hematologic toxicity.
• Creatinine clearance below 30 mL/min: Fludarabine Phosphate is contraindicated (see Contraindications).

Hepatic impairment

Specific dose adjustment guidance for hepatic impairment is not well established; use Fludarabine Phosphate with caution and close monitoring in patients with significant hepatic dysfunction.

Administration requires appropriate premedication, hydration, and monitoring for tumor lysis syndrome in patients with high tumor burden. Fludarabine Phosphate must be administered only by personnel trained in the handling and administration of cytotoxic chemotherapy.

Common

• Bone marrow suppression: neutropenia, thrombocytopenia, anemia (very common and often dose-limiting with Fludarabine Phosphate).
• Fever, chills, and increased susceptibility to infection.
• Nausea, vomiting, diarrhea, and loss of appetite.
• Fatigue, generalized weakness, and malaise.

Serious (require prompt medical attention)

• Severe neurotoxicity (agitation, confusion, visual disturbances, and rarely coma or blindness), particularly at higher-than-recommended doses of Fludarabine Phosphate.
• Autoimmune hemolytic anemia (see Precautions and Warnings).
• Pulmonary toxicity/pneumonitis.
• Tumor lysis syndrome in patients with high tumor burden.
• Secondary malignancies (e.g. myelodysplastic syndrome, acute myeloid leukemia) with long-term use of Fludarabine Phosphate.

Report any severe or persistent side effect of Fludarabine Phosphate to the treating oncologist promptly.